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Abstract 
Background: To compare the risk and severity of 
development of Dengue Hemorrhagic Fever (DHF) 
and Dengue Shock Syndrome(DSS) in patients 
receiving Vitamin D supplement compared to those 
not receiving it. 
Methods: Diagnosed patients of DF  (n=124) were 
enrolled in this comparative study. Patients were 
randomized into two groups having 62 participants 
in each group. Group A received single dose of 
200,000 IU Vitamin D and Group B received no 
intervention.  Both groups were followed for 
development of DHF or DSS.  Chi square was 
applied to compare the groups. 
Results: One patient (1.6%) in Group A developed 
DHF. Seventeen (27%) patients in Group B 
progressed to DHF. The relationship between 
Vitamin D and progression to DHF  was significant, 
X2 (2, N=170) =16.43, p= 0.000). The calculated 
relative risk was 0.0588 (95% confidence interval, 
.0081 to .4285; p  for trend = 0.0588). 
Conclusion: Vitamin D decreases the risk of DHF 
and may have a role in management of dengue fever. 
Key Words: Vitamin D, Dengue fever, Dengue 
haemorrhagic fever   
Introduction  
Dengue is a febrile illness that is a major cause of 
morbidity throughout the tropical and subtropical 
regions. It is a caused by a flavivirus with four distinct 
serotypes (DV-1, DV-2, DV-3, and DV-4). DHF is 
characterized by all the symptoms of Dengue fever  
(DF) along with haemorrhagic manifestations such as 
spontaneous bleeding, decrease in platelet count and 
evidence of increased vascular permeability noted as 
increased haemo-concentration or pleural effusion or 
ascites. 1 Virus spreads between humans by mosquito 
vectors of the Aedes genus, i.e, Aedes aegypti and 
Aedes albopictus.2  Approximately 2.5 billon people 
are at risk of getting infection and 50 million cases of 
dengue fever are reported every year.3 Infection with 
any of the serotypes may be asymptomatic in the 
majority of cases or may result in a wide spectrum of 
clinical symptoms, known as Dengue fever. The 
symptoms of dengue fever range from a mild flu-like 
syndrome to the most severe forms of the disease, 
DHF, which includes coagulopathy and increased 
vascular permeability. DHF may progress to 
hypovolemic shock known as DSS.4 In Asia the risk of 
developing severe disease is greater in Dengue fever-
infected children (≤15 years) than in adults.5 
The life-threatening DSS stage occurs at the time of or 
shortly after drop in blood pressure, which is 
characterized by a rapid, weak pulse, narrow pulse 
pressure (≤20 mm Hg) or hypotension with cold, 
clammy skin in the early stage of shock. This may soon 
progress to more serious form of shock if patients do 
not receive prompt and appropriate treatment, in 
which pulse and blood pressure become undetectable, 
resulting in death within 12 to 36 h after onset of 
shock.6  
Low blood calcium levels have been associated in 
Dengue. 7 Calcium has proven to be essential for 
cytotoxic activity of the dengue type 2 viruses (DV)-
induced macrophage cytotoxic (CF2).8 Calcium 
appears to play a role in the induction of dengue-
specific T-helper cells. Dengue antigen has been shown 
to increase the influx of calcium into T-cells. The 
proliferation of dengue-specific T-helper cells appears 
to be dependent on calcium and is inhibited in the 
absence of  calcium and by calcium channel antagonist 
drugs.9 There is some evidence that the production of 
nitrite in response to dengue virus infection is also 
calcium dependent and can be inhibited by calcium 
channel blocking drugs. 10 
Prevention and control of dengue and DHF has 
become the need of time with the expanding 
geographic distribution of disease and increased 
disease incidence in the past 20 years.11 Unfortunately, 
tools available to prevent dengue infection are very 
limited. Despite considerable work on vaccine for DF 
and DHF over the years, an effective safe vaccine is yet 
to be developed because of various obstacles. 
Mosquito prevention is also an important step in 
eradication of dengue fever. 12-14 
Few studies have also discussed role of Vitamin D in 
reducing the severity of DF,DHF and DSS. A case 
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series published in 2009 showed 5 patients receiving 
Vitamin D had overall improvement of clinical 
condition and reduced symptoms of DF.15  A Brazilian 
study found increase in Vitamin D binding protein in 
DF.16 The possible explanation of anti- dengue effects 
of vitamin D is because of involvement of cathelicidin 
(in the form of LL-37), human beta defensin 2, and 
through the release of reactive oxygen species.17 
Presently it is believed that patient of DF will never 
progress to DHF or DSS but wide variation in severity 
and outcome of disease make this doubtful.  
 
Patients and Methods 
A total of 124 patients with diagnosed dengue fever, 
who fulfilled the inclusion criteria were enrolled in to 
the study from 01.9.2016 to 31.1.2017 from  Benazir 
Bhutto Hospital after getting ethical review board 
approval. Patients were randomized to two groups 
having 62 participants each. Group A received 200,000 
IU Vitamin D and Group B received no intervention.  
Both groups were followed for development of dengue 
hemorrhagic fever or dengue septic shock.  Data was 
recorded in self-structured questionnaire. Categorical 
data was presented as frequencies.  Pearson’s Chi 
square was applied to compare the proportion of 
patients in each study group who will develop DHF & 
DSS. Relative Risk was measured along with 95% 
confidence intervals to compare the risk of 
development of DHF & DSS in both study groups. 
Significant value was < 0.05. 
 
Results 
Total of 124 patients were enrolled after informed 
consent. Mean age was 33.43 ± 16.20 
Table 1: Dengue Fever- variables at presentation  
Variables Mean Std. 
Deviation 
Age (Years) 33.43 16.22 
Calcium  at admission (mg/dl) 8.81 .42 
Albumin at admission (g/l) 4.44 3.65 
Platelet at admission (X109 /l)  108.90 40.24 
HCT at admission(%) 41.9 4.62 
WBC at admission(X109 /l) 3.73 1.27 
Platelet at discharge(X109 /l) 117.15 49.38 
HCT at discharge (%) 40.19 5.12 
WBC at discharge(X109 /l) 4.56 1.51 
 
. Mean calcium level at admission was 8.81 ± 0.42. 
Mean platelet at admission was 108.90 ± 40.24. Mean 
platelet at discharge was 117.15 ± 49.38 (Table 1).Most 
of the patients were admitted on 3rd ,4th and 5th 
day(n=105)91.6% (Table 2). 
One patient (1.6%) in Group A receiving in Vitamin D 
supplements developed dengue hemorrhage fever. 
Seventeen (27%) patients in Group B not receiving 
Vitamin D supplements progressed to dengue 
hemorrhagic fever. None of the patients developed 
DSS (Table 3). The relationship between Vitamin D 
supplements and Progression to DHF was significant, 
X2 (2, N=170) =16.43, p= 0.000. Vitamin D decreases 
the risk and severity of DHF. The calculated relative 
risk was 0.0588 (95% confidence interval, .0081 to 
.4285; p for trend = 0.0588) 
Table 1: Total No of Days of Illness 
No of Days of Illness Frequency Percent 
 1st Day 2 1.6 
2nd day 7 5.6 
3rd day 37 29.8 
4th day 32 25.8 
5th day 36 29.0 
6th day 10 8.1 
Total 124 100.0 
Table 3: Vitamin D Supplementation 
Vitamin D Dengue Fever Dengue Haemorrhagic 
Fever 
No(%) N0(%) 
Yes 61(98.4) 1(1.6) 
No 45(73.0) 17(27.0) 
Discussion 
In present  study, in group receiving Vitamin D, there 
was fewer progression of DF to DHF. The relationship 
between Vitamin D supplements and Progression to 
DHF was significant, X2 (2, N=170) =16.43, p= 0.000. 
Vitamin D decreases the risk and severity of DHF. The 
calculated relative risk was 0.0588 (95% confidence 
interval, .0081 to .4285; p for trend = 0.0588). A  
Mexican study investigated the effect of treatment 
with vitamin D3 on two types of human cell lines 
(hepatic Huh-7 and monocytic U937) infected with 
DENV.18 Pureta found that exposure to 1,25-dihydroxy 
vitamin D3 significantly reduced the number of 
infected cells, particularly in monocytic cells, and 
lowered the production of pro-inflammatory 
cytokines.18Vitamin D3 significantly reduced the levels 
of pro-inflammatory cytokines (TNF-α, IL-6, IL-12p70 
and IL-1β) produced by infected U937 cells. These 
results suggest that vitamin D3 may represent a 
potentially useful antiviral compound. According to 
another study, vitamin D supplementation altered IL-
12 expression and dendritic cell maturation.19 Giving 
vitamin D to dengue patients improved clinical 
condition.19 Standard treatment for dengue 
management is give electrolytic solutions 
administration, bed rest, measurements of body 
temperature, blood pressure, haematocrit, platelet 
count, and administration of antipyretics.19 
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Host nutritional status is a strong predictor of 
immunity.20 Host nutritional status or micronutrient 
supplementation as adjuvant therapy could lower the 
probability of progressing from DENV infection to 
overt/severe forms of disease or reduce disease 
severity in patients.22 Low blood calcium levels have 
been associated with Dengue.7  The mean calcium 
level at admission at our study was 8.81±0.42.  
In present study only 1 patient on Vitamin D 
developed DHF.  Alagarasu et al  showed that there 
might be an association related to the inducing effect 
of vitamin D on Fcγ-receptor expression. Fcy receptor 
enhances viral entry into cells, possibly leading to 
higher viral load in dengue cases with secondary 
infection and the development of DHF or dendritic 
cell-specific intercellular adhesion. Studies Vitamin D 
might influence viral entry into cell. 21   
Albuquerque compared protein levels in the plasma of 
patients with severe DF with the protein levels of 
healthy individuals and found that a one of the 
proteins showing a significant increase in DF patients 
was vitamin D-binding protein.18 Sánchez-Valdéz 
observed a significant increase in platelet count on 
receiving vitamin D in their clinical trial. The average 
platelet count changed from 136,000 ± 69,508 
cells/mm3 before treatment to 179,600 ± 56,584 
cells/mm3 after treatment.15 In our study the mean 
platelet at admission was 108.90±40.24, while at 
discharge it was 117.15±49.38.  
The mean haematocrit at admission was 41.9±4.62 
while at discharge it was 40.19±5.12. Sánchez-Valdéz 
also observed a significant improvement in the overall 
clinical condition of the patients as well as reduction in 
the duration of signs and symptoms of the infection. 
Sánchez-Valdéz suggested that Vitamin D 
supplementation may possibly restore free calcium 
rapidly, leading to the reduced thrombocytopenia as 
seen in his trial. 
Conclusion 
Vitamin D may have a role in Dengue management. A 
larger clinical trial is needed to further investigate 
the relationship between Vitamin D and dengue 
management.  
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